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Abstract
Early fetal echocardiography (EFEC) is a fetal cardiac ultrasound analysis performed between the 12th and 16th
week of pregnancy (compared with the usual 18-22 weeks). In the last 10 years, the introduction of “aneuploidy
sonographic markers” in screening for cardiac defects has led to a shift from late second to end of the first trimester
or beginning of the second trimester of pregnancy for specialist fetal echocardiography. In this prospective study,
early obstetric screening was performed between January 2014 and October 2015, using “aneuploidy sonographic
markers” following SIEOG Guidelines 2014. These parameters were then collected and strategically combined in an
evaluation score to select the group of pregnancies for performing EFEC, in accordance with the American Society
of Echocardiography guidelines for fetal Echocardiography. All second-level examinations were performed
transabdominally using a 3D convex volumetric probe with frequency range of 4-8 MHz (Accuvix – Samsung). The
outcome data included transabdominal fetal echocardiography from 18 weeks to term and after birth. Overall, 99
pregnant women in the first trimester underwent EFEC (95 singleton and 4 twin pregnancies). Specifically, 30
fetuses were evaluated for extra-cardiac anomalies evidenced by obstetric screening (30%), 25 for family history of
congenital heart diseases (25%), 8 for family history of genetic-linked diseases (8%), 4 for heart diseases suspected
by obstetric screening (4%) and 19 by normal screening (19%). Was detected 11 (10.7%) CHD, when EFEC
detected CHD, were compared to those performed later in pregnancy (18 weeks GA-term), a high degree of
diagnosis correspondence was evidenced. The higher sensitivity value of EFEC vs late-FE, in comparison with the
post-natal value, coupled with the high EFEC specificity shown vs both the end points, enabled us to consider it as a
really reliable diagnostic technology, at least in perienced hands. The introduction of a key combination of the more
sensitive obstetric and cardiologic variables should facilitate the formulation of a possible flow-chart as a guide for
CHD at-risk pregnancies.
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Introduction
Congenital Heart Diseases (CHD) are the most common
malformations, occurring in 0.8% of the general population. While it is
possible to screen CHD during fetal life by a prenatal routine
ultrasound examination, this can identify only 60 % of CHD [1]. Major
cardiac defects need specialist fetal echocardiography for complete
diagnosis and counseling. It is necessary to improve the methods used
to screen high-risk groups of pregnancies by standardizing the clinical
evaluation of the maternal-placental-fetal unit with the use of a
diagnostic protocol that can be shared by obstetricians, genetistics and
fetal echocardiographers. The data obtained may then be used as a
basis for the identification of sensitive criteria for formulating a
clinical-sonographic score and flow-chart as a guide for the diagnostic
and therapeutic management of CHD pregnancies.
CHD at-risk groups identified for referral through routine screening
include: family history of CHD, maternal pathologies such as diabetes
mellitus and connective diseases, maternal exposure to teratogens, and,
in the last 10 years, the introduction of “aneuploidy sonographic
markers” in screening for cardiac defects (NT thickness, abnormal flow
through the ductus venosus and across the tricuspid valve) [2-7].
This approach has led to a shift from late second to end of first or
beginning of second trimester of pregnancy for specialist fetal
echocardiography. Fetal cardiac ultrasound analysis performed
between the 12th and 16th week of pregnancy (compared with the
usual 18-22 weeks) is defined as Early Fetal Echocardiography (EFEC)
[8-15].
An important preliminary consideration is that the most complex
CHDs do not develop in hearts that appear to be normal at an early
stage and present similar images in the 1st, 2nd and 3rd trimesters
(d/l-Transposition of Great Arteries, Hypoplastic Left Ventricle
Syndrome, Atrioventricular Septal Defect, Double Outlet Right
Ventricle, Tricuspid Atresia, Mitral Atresia, Pulmonary Atresia, Total
Total Anomalous Pulmonary Venous Return, large Ventricular Septal
Defect).
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Our general working hypothesis is that the strategic combination of
already acquired or new diagnostic and biotechnological tools (such as
“aneuploidy sonographic markers”, EFEC, genetic analysis) could be
analyzed on the basis of their specific statistic reliability and used as
key criteria for a clinical score to be included in the management of
CHD “at risk” pregnancies.
Within this working hypothesis, the specific objective of the present
study is to test the effective reliability of EFEC in selected CHD at-risk
pregnancies in order to figure out the key clinical diagnostic elements
to be used as a guide for fetal-maternal unit management.
Score 0 1 2 3
Age < 30 31-35 > 35 /
NT < 1 1-2 2,1-2,9 > 3
Nasal Bone Present / Hypoplastic Absent
Tricuspidregurgitation Absent / / Present
Ductus venosus wave a Positive / Absent Negative
Heart rate 151-170 b/m 140-150 b/m > 170 b/m < 140 b/m
History Negative • Thyroid disease • Drugs
• Previous CHD
• Diabetes mellitus
• Autoimmunity
• Maternal heart disease
• Metabolic disease
• Twins
Table 1: Score to select pregnancies for EFEC.
Minor defects Major defects
Cardiomegaly
Ventricular septal defects
Disproportion:
LV<RV
AO<PA
PA<AO
RV<LV
RA > LA
Atrioventricular septal defect
Trasposition of the great vessels
Tetralogy of fallot
Hypoplastic left heart ventricle
Pulmonary atresia
Complex cardiopathies
LV : Left Ventricle; RV: Right Ventricle; AP: Pulmonary Artery; AO: Aorta
Table 2: CHD classification in EFEC.
Methods
In this prospective intervention study, early obstetric screening was
performed between January 2014 and October 2015, using “aneuploidy
sonographic markers” following SIEOG Guidelines 2010 [16],
including the first trimester ultrasound markers of early fetal right
heart dysfunction. These parameters were then collected and
strategically combined in an evaluation score (Table 1), to select the
group of pregnancies for performing EFEC. Briefly, this evaluation
method was considered as more indicative for a possible CHD when a
cut-off level of > 4 was obtained by assigning an indicative value from
0 to 3 to each task, on the basis of statistical data analysis performed by
our Obstetric Unit.
The study was approved by the Ethics Committee of the Policlinico
Umberto I, Sapienza University of Rome.
A total of 99 pregnant women (103 fetuses) underwent EFEC
screening (the first antenatal EFE screenings took place at 11-12 weeks
gestation, based on the early fetal echography (EFE). At the first visit,
the women received prescreening genetic counseling and an
information booklet. They were informed of the limitations of the
screening method and info med consent was obtained. Maternal family
and personal health details were inserted in an internally networked
database in Access format.
In addition to the cited score, the first level of early fetal heart study
was performed by obstetricians at the Prenatal Diagnosis Unit for the
evaluation of abdominal situs and heart position within the chest, four-
chamber view, atrioventricular valve offsetting, ventricle filling with
Color Doppler (CD), pulmonary artery-aorta crossing (X sign) with
CD, forward flow and equal size at the confluence of the aortic arch
and arterial ductus (V sign) [10].
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The second cardiac diagnostic level (EFEC) concerns the specific
cardiologic analysis, which was performed in accordance with the
American Society of Echocardiography guidelines for fetal
Echocardiography (AHA 2014 Circulation) [17] (Figures 1-3).
GR.1 n. 25 GR.2 n. 4 GR. 3 n. 30 GR. 4 n. 13 GR. 5 n. 8 GR. 6 n. 19
(25%) (4%) (31%) (13%) (8%) (19%)
Family history
of CHD
Suspected CHD (First level cardiac
obstetric evaluation)
Obstetric screening
alterations (score)
Maternal
disease
Family history of chromosomal/genetic
disorders
Control
Table 3: Obstetric selection of groups of pregnancies considered for EFEC evaluation: total n. 99. (Fetuses n. 103) (100%).
Groups: n. CHD suspected/
detected
GA (Weeks) EFE Indications Early (12-16 Weeks) Late (18 weeks-
end pregnancy)
Outcome
Top/Intra
Uterine Death
(IUD)
Postnatal
1: 2 14 Family history of long QT
syndrome
Muscular VSD suspected
long QT syndrome for
relative bradycardia
Confirmed Confirmed
14 Family history of CHD Normal Small Muscular
VSD
Confirmed
2: 4 15 Suspected AVSD VSD and Suspected
Aortic Coarctation+
Monosomy X
N.D. Top
15 Suspected AVSD AVSD-FALLOT + Trisomy
21 (Figure 1)
N.D. Top
15 Suspected HLVS, Single
Umbilical Artery
Suspected Shone
Syndrome (Figure 2)
Confirmed Top
14 Suspected CHD (Dilated
ICV)
Agenesis Ductus
Venosus: Umbilical Vein -
> Iliac Veins-> ICV (Figure
3)
Confirmed Right Lower Limb
Venous Flow
Insufficiency
3: 6 12 Cystic Hygroma,
Increased NT and
Tricuspid Regurgitation
VSD, Tricuspid
Regurgitation Trisomy 21
N.D Top
14 Cystic Hygroma,
Hyperchoic Bowel Loops
Aortic Valve Stenosis Confirmed Confirmed
Valvuloplasty in
Second Day
15 Increased NT, Hydrops HLVS + Trisomy 18 Confirmed IUD
16 Cystic Hygroma DORV TGV AoCO Confirmed Confirmed, Switch
Operation and
Repaired AoCO
16 Polymalformative
Syndrome
LV < RV and AO < AP N.D Top
14 Cystic Hygroma, Hydrops,
Nasal Bone Hypoplasia
Tricuspid Regurgitation
Left Ventricle Prevalence
N.D. Top
TOP: Termination of Pregnancy; N.D: Not Detected; VSD: Ventricular Septal Defect; AVSD: Atrioventricular Septal Defect; HLVS: Hypoplastic Left Ventricle Syndrome;
ICV: Inferior Vena Cava; CHD: Congenital Heart Disease; DORV: Double Outlet Right Ventricle; TGV: Transposition of the Great Vessels; AoCO: Coarctation of the
Aorta; LV: Left Ventricle; RV: Right Ventricle; AP: Pulmonary Artery.
Table 4: EFEC and Late-FE detected-CHD within the groups.
All second-level examinations were performed transabdominally
using a 3D convex volumetric probe with frequency range of 4-8 MHz
(Accuvix A30-Samsung).
All the cardiac scan digital video-clips recorded were stored in the
ultrasound equipment and subsequently collected and analyzed.
The outcome data included transabdominal fetal echocardiography
from 18 weeks to term and after birth.
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Applying the systemic sequential approach, 2D, CD and Power
Doppler (PW) were used to visualize and analyze the images and the
flow signals obtained by four- chamber view with atrioventricular
valve setting, right and left ventricle outflow tracts and crossing, aortic
and ductal arches, sweep from four- chamber to three-vessel view, and
to evaluate ventricular function and heart rhythm with mechanical PR
interval [11].
Figure 1: GA 15 Ws AVSD and tetralogy of fallot. AVSD:
Atrioventricular Septal Defect (Arrow); IPS: Infundibular
Pulmonary Stenosis (Arrow).
Figure 2: GA 15 Ws shone syndrome. LV: Left Ventricle; RV: Right
Ventricle; AO: Aorta (arrow); PA: Pulmonary Artery.
First trimester classification of CHDs differs from the usual later
and post-natal classification [10], when a complete diagnosis can be
performed (Table 2).
Statistical Analysis
Late-FE and Post-natal Echocardiography were considered as
diagnostic end-points for each EFEC-detected CHD. Sensitivity,
specificity and predictive values of EFEC diagnosis, as well as receiver
operating characteristic (ROC), were calculated following a binary
classification test.
Results
EFEC indications and general clinical features of the pregnant
women analyzed in our Unit are summarized in Table 3.
Overall, 99 pregnant women in the first trimester underwent EFEC
(95 singleton and 4 twin pregnancies). Specifically, 30 fetuses were
evaluated for extra-cardiac anomalies evidenced by obstetric screening
(30%), 25 for family history of congenital heart diseases (25%), 8 for
family history of genetic-linked diseases (8%), 4 for heart diseases
suspected by obstetric screening (4%) and 19 by normal screening
(19%).
As shown in Table 4, when EFEC-detected CHD were compared to
those performed later in pregnancy (18 weeks GA-term), a high degree
of diagnosis correspondence was evidenced.
Figure 3: GA 15 Ws agenesis of ductus venosus. Umbilical vein
drains in iliac veins and inferior vena cava (Arrow). UV: Umbilical
Vein; IVC: Inferior Vena Cava.
Statistical Analysis for the evaluation of EFEC sensitivity and
specificity in relation to the end-points considered (late FE and post-
natal echocardiography) is shown in Table 4. The higher sensitivity
value of EFEC vs late-EFEC, in comparison with the post-natal value,
coupled with the high EFEC specificity shown vs both the end points,
enabled us to consider it as a really reliable diagnostic technology, at
least in experienced hands.
Discussion
There is a growing body of evidence that most of the major cardiac
abnormalities can be diagnosed from 12-16 weeks of gestation.
Furthermore, the reason for performing EFEC is that the combined
EFEC-NT (nuchal translucency) approach (11th-13th week) gives a
60-70% increase in detection rate for CHD. Combined EFEC-NT
analysis is also justified by the high CHD frequency in genetic
syndromes and the similarity of anatomic relations between cardiac
structures at 11-13 ws GA and those of the second trimester.
Thus, early evaluation could imply better decision making.
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In this prospective study of first-trimester screening, the sequential
combination of the obstetric “aneuploidy sonographic markers” with
EFEC, performed on a selected group of 99 pregnant women, 11 CHD
were detected, showing an excellent rate of reliability when compared
with the regular late FE, with 91.7% sensitivity and 100% specificity
(100% PPV and 98.8% PNV); only one case of small muscular VSD
was diagnosed in late echo. These results were partly confirmed when
EFEC was compared with the early post-natal control (neonatal
period), with a 84.6 % sensitivity and 100% specificity (100% PPV,
97.7% PNV). The reduced sensitivity rate is due to postnatal diagnosis
of a very slight pulmonary valve stenosis and an isolated
uncomplicated aortic bicuspid valve: cardiac anomalies which are
known to be rarely detectable before birth (Table 5).
Early VS Late Early VS Postnatal Late VS Postnatal
Sensitivity: 91.7% Sensitivity: 84.6% Sensitivity: 85.7%
Specificity: 100% Specificity: 100% Specificity: 100%
Positive Predictive Value (PPV): 100% Positive Predictive Value (PPV): 100% Positive Predictive Value (PPV): 100%
Negative Predictive Value (NPV): 98.8% Negative Predictive Value (NPV): 97.7% Negative Predictive Value (NPV): 97.7%
Table 5: EFEC-CHD detection sensitivity, specificity, PPV, NPV, evaluated in comparison with the diagnostic end-point (Post-Natal
Echocardiography).
The technical limits of EFEC are CRL < 50 mm, an increase of
maternal Body mass index (BMI), unfavorable fetal position and a
possible progression of cardiac disease especially in outflow
obstructions [12,13]. This means that the pregnant women should be
informed about the limits of early screening and also recommended to
have a further scan as from 18 weeks for a more complete diagnosis.
Nevertheless, taking into account the accuracy of this technology,
EFEC gives the parents the opportunity to be more aware and to have
more time to make an informed decision regarding continuation of the
pregnancy with reduced long-term psychological sequelae. In this way,
if the couple decides to continue the pregnancy, the timing, location,
mode of delivery and direct postnatal care can be planned, with a
consistent improvement of postnatal outcome. Where the EFEC shows
no evidence for a major cardiac defect, it allows earlier reassurance of
couples considered at high risk for CHD. Exclusion of a complex
cardiopathy at an early stage of pregnancy is particularly reassuring for
parents with a child affected by CHD in a previous pregnancy [14].
Conclusion
Overall, EFEC may be considered feasible, highly sensitive and
specific when performed by experienced fetal cardiologists.
Moreover, the introduction of a key combination of the more
sensitive obstetric and cardiologic variables, including the use of new
technologies [18], should facilitate the formulation of a possible flow-
chart as a guide for CHD at-risk pregnancies
Studies are currently under way in our Echo-Lab to develop a flow-
chart by introducing a more complete clinical score which could also
include new CHD-sensitive molecular markers (miRNAs) detectable
in maternal peripheral blood [19].
Acknowledgments
We wish to acknowledge the support of Samsung Electronics Spa,
Hme division, Health & Medical Equipment, and the Piccolo Grande
Cuore Onlus and the Istituto Pasteur - Cenci Bolognetti foundation,
the two associations that enabled us to purchase the equipment.
We also wish to thank Dr. Violante Di Donato developing statistical
analysis and Dr. Lardini Fabrizio for informatic support.
References
1. Van Velzen C, Clur S, Rijlaarsdam M, Bax C, Pajkrt E, et al. (2015)
Prenatal detection of congenital heart dis-ease-results of a national
screening programme. BJOG.
2. Borrell A (2009) Promises and pitfalls of first trimester sonographic
markers in the detection of fetal aneu-ploidy. Prenat Diagn 29: 62-68.
3. Huggon IC, DeFigueiredo DB, Allan LD (2003) Tricuspid regurgitation in
the diagnosis of chromo-somal anomalies in the fetus at 11-14 weeks of
gestation. Heart 89: 1071-1073.
4. Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH (2011)
Contribution of fetal tricuspid regurgitation in first-trimester screening
for major cardiac defects. Obstet Gynecol 117: 1384-1391.
5. Ghi T, Huggon IC, Zosmer N, Nicolaides KH (2001) Incidence of major
structural cardiac defects associated with increased nuchal translucency
but normal karyotype. Ultrasound Obstet Gynecol 18: 610-614.
6. Maiz N, Plasencia W, Dagklis T, Faros E, Nicolaides K (2008) Ductus
venosus Doppler in fetuses with cardiac defects and increased nuchal
translucency thickness. Ultrasound Obstet Gynecol 31: 256-260.
7. Prefumo F, Sethna F, Sairam S, Bhide A, Thilaganathan B (2005) First-
Trimester Ductus Venosus, Nasal Bones, and Down Syndrome in a High-
Risk Population. Obstet Gynecol 105: 1348-1354.
8. Clur SA, Bilardo CM (2014) Early detection of fetal cardiac
abnormalities: how effective is it and how should we manage these
patients? Prenat Diagn 34: 1235-1245.
9. Lombardi CM, Bellotti M, Fesslova V, Cappellini A (2007) Fetal
echocardiography at the time of the nuchal translucency scan. Ultrasound
Obstet Gynecol 29: 249-257.
10. Persico N, Moratalla J, Lombardi CM, Zidere V, Allan L, et al. (2011)
Fetal echocardi-ography at 11-13 weeks by transabdominal high-
frequency ultrasound. Ultrasound Obstetr Gynecol 37: 296-301.
11. Pike JI, Krishnan A, Donofrio MT (2014) Early fetal echocardiography:
congenital heart disease de-tection and diagnostic accuracy in the hands
of an experienced fetal cardiology program. Prenat Diagn 34: 790-796.
12. Volpe P, De Robertis V, Campobasso G, Tempesta A, Volpe G, et al.
(2012) Diagnosis of Congenital Heart Disease by Early and Second-
Trimester Fetal Echocardiography. J Ultrasound Med 31: 563-568.
13. Zidere V, Bellsham-Revell H, Persico N, Allan LD (2013) Comparison of
echocardiographic findings in fetuses at less than 15 weeks’ gestation with
later cardiac evaluation. Ultrasound Obstet Gynecol 42: 679-686.
14. Renna MD, Pisani P, Conversano F, Perrone E, Casciaro E, et al. (2013).
Sonographic markers for early diagnosis of fetal malformations. World J
Radiol 5: 356-371.
Citation: Ventriglia F, Caiaro A, Giancotti A, Abed MM, Ceccacci I, et al. (2016) Reliability of Early Fetal Echocardiography for Congenital Heart
Disease Detection: A Preliminary Experience and Outcome Analysis of 102 Fetuses to Demonstrate the Value of a Clinical Flow-Chart
Designed for At-Risk Pregnancy Management. Pediat Therapeut 6: 270. doi:10.4172/2161-0665.1000270
Page 5 of 6
Pediat Therapeut
ISSN:2161-0665 Pediatrics, an open access journal Volume 6 • Issue 1 • 1000270
15. Carvalho JS, Moscoso G, Tekay A, Campbell S, Thilaganathan B, et al.
(2004). Clinical impact of first and early second trimester fetal
echocardiography on high risk pregnancies. Heart 90: 921-926.
16. Edizione (2010) Società Italiana di Ecografia Ostetrico Ginecologica.
LINEE GUIDA SIEOG, EDITEAM.
17. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS,
et al. (2014) Diagnosis and Treatment of Fetal Cardiac Disease: A
Scientific Statement From the American Heart Association. Circulation
129: 2183-2242.
18. Espinoza J, Lee W, Viñals F, Martinez JM, Bennasar M, et al. (2014)
Collaborative Study of 4-Dimensional Fetal Echocardiography in the First
Trimester of Pregnancy. J Ultrasound Med 33: 1079-1084.
19. Omran A, Elimam D, Webster KA, Shehadeh LA, Yin F (2013)
MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle.
Cardiol Young 23: 642-655.
 
Citation: Ventriglia F, Caiaro A, Giancotti A, Abed MM, Ceccacci I, et al. (2016) Reliability of Early Fetal Echocardiography for Congenital Heart
Disease Detection: A Preliminary Experience and Outcome Analysis of 102 Fetuses to Demonstrate the Value of a Clinical Flow-Chart
Designed for At-Risk Pregnancy Management. Pediat Therapeut 6: 270. doi:10.4172/2161-0665.1000270
Page 6 of 6
Pediat Therapeut
ISSN:2161-0665 Pediatrics, an open access journal Volume 6 • Issue 1 • 1000270
